| Code | CSB-RA016023MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of REGN-9035, developed for studies centered on the natriuretic peptide receptor 1 (NPR1, also known as NPRA/GC-A), a membrane-bound guanylate cyclase receptor that transduces atrial and brain natriuretic peptide (ANP/BNP) signaling into intracellular cGMP production. NPR1 activation is a core component of cardiovascular homeostasis, linking cardiac stretch–induced natriuretic peptide release to downstream effects on vascular tone and fluid balance. Because endogenous ANP/BNP peptides are rapidly cleared in circulation, durable experimental modulation of the NPR1–cGMP axis is often necessary to interrogate sustained hemodynamic biology and target engagement in translational research.
REGN-9035 was designed as an anti-REGN5381 reversal antibody, providing a controllable “off-switch” for REGN5381—an investigational NPR1 agonist monoclonal antibody reported to drive predictable hemodynamic effects through NPR1 activation. As a biosimilar research reagent, this antibody supports mechanistic and pharmacology workflows that require timed reversal of NPR1 agonist-antibody activity, including assay development for agonist–reversal pairing, PK/PD modeling of antibody-mediated NPR1 modulation, and studies examining the duration and reversibility of NPR1-driven vascular responses independent of endogenous peptide kinetics.
There are currently no reviews for this product.